治験レーダーAI | ||
|---|---|---|
治験 NCT05106374（対象：造血およびリンパ系細胞腫瘍、非小細胞肺癌）は実施中／登録終了です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
オハイオ州立大学Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
I. To validate the accuracy and predictive ability of the Cancer and Aging Research Group (CARG) Chemo-Toxicity calculator in untreated patients with hematologic malignancy and non-small cell lung cancer, as well as relapsed patients with a hematologic malignancy intended to begin chimeric antigen receptor (CAR) T cell therapy.
Ia. Determine if the CARG Chemo-Toxicity calculator predicts grade 3-5 toxicity in older adult patients with hematologic malignancy undergoing treatment.
Ib. Determine if CARG Geriatric Assessment (GA) metrics predict grade 3-5 toxicity in older adults with hematologic malignancy undergoing treatment.
Ic. Identify the association between frailty metrics and relative dose intensity in older adults with hematologic malignancy.
Id. To evaluate feasibility of CARG GA and functional assessment implementation in older adults with non-small cell lung cancer (NSCLC).
SECONDARY OBJECTIVES:
I. To determine the relationship of frailty metrics (CARG chemo-toxicity calculator and geriatric assessment metrics) with health related quality of life (HRQL) over time.
II. To identify the relationship of frailty metrics (chemo-toxicity calculator and GA metrics) with physical function as measured by the short physical performance battery (SPPB).
III. To determine the association of molecular markers of aging (OSU_Senescence, Hovarth epigenetic clock/deoxyribonucleic acid [DNA]ge, inflammatory cytokines, changes in peripheral blood T lymphocyte subsets) with risk of chemotherapy toxicity using the Chemo-Toxicity calculator and other prognostic factors (e.g. age, disease, stage, body composition by imaging).
IV. In the NSCLC cohort we will determine the association between treatment efficacy and toxicity with changes in the stool microbiome.
OUTLINE:
Patients complete questionnaires over 30-40 minutes about daily activity and feelings, complete thinking and walking tests over 10 minutes, and undergo collection of blood samples before the first dose of chemotherapy and 90, 180, and 365 days after first dose of chemotherapy. Patients with non-small lung cancer also undergo collection of stool sample.
After completion of study treatment, patients are followed up every 6 months.
FITNESS: Calculating Risk of Chemotherapy Toxicity in Older Adults
| 参加グループ/群 | 介入/治療法 |
|---|---|
Observational (questionnaire, assessment, biospecimen) Patients complete questionnaires over 30-40 minutes about daily activity and feelings, complete thinking and walking tests over 10 minutes, and undergo collection of blood samples before the first dose of chemotherapy and 90, 180, and 365 days after first dose of chemotherapy. Patients with non-small lung cancer also undergo collection of stool sample. | 生体試料採取 Undergo collection of blood and stool samples 認知評価 Complete thinking test 身体能力検査 Complete walking test 生活の質評価 Ancillary studies アンケート管理 Complete questionnaire |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Prognostic ability of the CARG chemotoxicity calculator in patients newly diagnosed with hematologic malignancy | 365 days after first dose of chemotherapy | |
Predictive ability of the Cancer and Aging Research Group (CARG) Chemo-Toxicity calculator | 365 days after first dose of chemotherapy | |
Predictive ability of Chemo-Toxicity calculator to predict grade 3-5 toxicity | Will fit a Cox regression model for time to toxicity (grades 3-5) containing the baseline chemo-toxicity risk score as the only predictor. The overall ability of the model to distinguish grade 3-5 from grade 1-2 toxicity will be evaluated using Harrell's C-statistic, which can be viewed as a generalization of the area under the curve measurement for receiver operator characteristics (ROC's) curves based on binary outcome data. A 95% confidence interval will be constructed for the C-statistic and if the lower bound is greater than 0.5 (expected value if the risk score is not predictive of toxicity) we will conclude that risk score is significantly able to distinguish between toxicity grades. | 365 days after first dose of chemotherapy |
Predictive ability of Geriatric Assessment (GA) metrics to predict grade 3-5 toxicity | Will fit a Cox regression model for time to toxicity (grades 3-5) containing the baseline chemo-toxicity risk score as the only predictor. The overall ability of the model to distinguish grade 3-5 from grade 1-2 toxicity will be evaluated using Harrell's C-statistic, which can be viewed as a generalization of the area under the curve measurement for ROC's curves based on binary outcome data. A 95% confidence interval will be constructed for the C-statistic and if the lower bound is greater than 0.5 (expected value if the risk score is not predictive of toxicity) we will conclude that risk score is significantly able to distinguish between toxicity grades. | 365 days after first dose of chemotherapy |
Association between frailty metrics and relative dose intensity (RDI) | Will explore the relationship of RDI and MAX2 (reduced and prescribed) with clinical and biologic factors of frailty. RDI (\>= 85% versus \[vs.\] \< 85%) will be treated as a continuous and dichotomous variable. The distribution of RDI and MAX2 will be examined graphically and transformed to normality as appropriate. Linear regression for continuous RDI and logistic regression for dichotomized RDI will be used to understand the relationship with RDI and independent variables (e.g. GA scores, age, short physical performance battery \[SPPB\] etc.) Stepwise regression will be used to identify significant clinical and biologic factors (e.g. OSU\_Senescence) that are independently associated with continuous or dichotomized RDI. | 365 days after first dose of chemotherapy |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Relationship of frailty metrics with health related quality of life over time | Linear mixed models will be used in the analyses. Each model will include effects of each prognostic variable of interest, time (baseline vs. end of treatment), and time-by-prognostic variable interactions to determine if the associations between the prognostic variables and the outcome differs at baseline and end of treatment. An unstructured covariance matrix will be used to model the relationship between outcome measurements from the same patient. | 365 days after first dose of chemotherapy |
Relationship of frailty metrics with physical function | Linear mixed models will be used in the analyses. Each model will include effects of each prognostic variable of interest, time (baseline vs. end of treatment), and time-by-prognostic variable interactions to determine if the associations between the prognostic variables and the outcome differs at baseline and end of treatment. An unstructured covariance matrix will be used to model the relationship between outcome measurements from the same patient. | 365 days after first dose of chemotherapy |
Molecular markers of aging with risk of chemotherapy toxicity using the Chemo-Toxicity calculator | Will determine the association of molecular markers of aging with risk of chemotherapy toxicity using the Chemo-Toxicity calculator and other prognostic factors (e.g. age, disease, stage, body composition by imaging). Linear mixed models will be used in the analyses. Each model will include effects of each prognostic variable of interest, time (baseline vs. end of treatment), and time-by-prognostic variable interactions to determine if the associations between the prognostic variables and the outcome differs at baseline and end of treatment. An unstructured covariance matrix will be used to model the relationship between outcome measurements from the same patient. | 365 days after first dose of chemotherapy |
- Untreated for a hematologic malignancy or NSCLC malignancy with intention to receive treatment (i.e., chemotherapy, immunotherapy, targeted agents, bone marrow transplant, or other) at the Ohio State University; or patients with a relapsed hematologic malignancy intended to begin CAR T cell therapy
- Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
- Prisoners are excluded from participation
- Any medical condition including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study procedures
オハイオ州立大学455 件のアクティブな治験を探索Ohio